Organization and Description of the Business	12 Months Ended
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of the Business	Organization and Description of the Business Trevena, Inc., or the Company, was incorporated in Delaware as Parallax Therapeutics, Inc. on November 9, 2007. The Company began operations in December 2007, and its name was changed to Trevena, Inc. on January 3, 2008. The Company is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company operates in one segment and has its principal office in Chesterbrook, Pennsylvania. Since commencing operations in 2007, the Company has devoted substantially all of its financial resources and efforts to research and development, including preclinical studies and clinical trials. The Company has never been profitable and has not yet commenced commercial operations. In January 2018, the United States Food and Drug Administration, or FDA, accepted the NDA submission for OLINVO, the Company's lead product candidate. The FDA also indicated that the Prescription Drug User Fee Act, or PDUFA, review date for the OLINVO NDA is November 2, 2018 and that it plans to hold an advisory committee meeting to discuss the NDA. If OLINVO ultimately receives regulatory approval, the Company plans to commercialize it in the United States, either on its own or with a commercial partner, for use in acute care settings such as hospitals and ambulatory surgery centers; outside the United States, the Company plans to commercialize OLINVO in certain countries with commercial partners. Since the Company's inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2017, the Company had an accumulated deficit of $357.5 million. The Company’s net loss was $71.9 million, $103.0 million and $50.5 million for the years ended December 31, 2017, 2016 and 2015, respectively. The Company expects its cash and cash equivalents of $16.6 million and marketable securities of $49.5 million as of December 31, 2017, together with interest thereon, to be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2019.

Organization and Description of the Business

Trevena, Inc., or the Company, was incorporated in Delaware as Parallax Therapeutics, Inc. on November 9, 2007. The Company began operations in December 2007, and its name was changed to Trevena, Inc. on January 3, 2008. The Company is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company operates in one segment and has its principal office in Chesterbrook, Pennsylvania.

Since commencing operations in 2007, the Company has devoted substantially all of its financial resources and efforts to research and development, including preclinical studies and clinical trials. The Company has never been profitable and has not yet commenced commercial operations. In January 2018, the United States Food and Drug Administration, or FDA, accepted the NDA submission for OLINVO, the Company's lead product candidate. The FDA also indicated that the Prescription Drug User Fee Act, or PDUFA, review date for the OLINVO NDA is November 2, 2018 and that it plans to hold an advisory committee meeting to discuss the NDA. If OLINVO ultimately receives regulatory approval, the Company plans to commercialize it in the United States, either on its own or with a commercial partner, for use in acute care settings such as hospitals and ambulatory surgery centers; outside the United States, the Company plans to commercialize OLINVO in certain countries with commercial partners.

Since the Company's inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2017, the Company had an accumulated deficit of $357.5 million. The Company’s net loss was $71.9 million, $103.0 million and $50.5 million for the years ended December 31, 2017, 2016 and 2015, respectively. The Company expects its cash and cash equivalents of $16.6 million and marketable securities of $49.5 million as of December 31, 2017, together with interest thereon, to be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2019.